U.S. Auto Components Stock News

In the second quarter of 2026, Axon Enterprise reported revenue of US$904.39 million versus US$668.54 million a year earlier, while quarterly net income eased to US$29.43 million from US$36.12 million, and the company raised its full-year 2026 revenue growth guidance to a range of 32% to 34%. Although Axon’s quarterly profit margin compressed compared with the prior year, its stronger first-half earnings and higher full-year revenue outlook highlight how growing demand for its public safety...

Atlas Energy Solutions earnings trigger fresh focus on costs Atlas Energy Solutions (AESI) is back in the spotlight after its Q2 2026 report showed a higher net loss alongside only a modest change in revenue, putting cost pressures and margins firmly on investors’ radar. See our latest analysis for Atlas Energy Solutions. At a share price of $10.67, Atlas Energy Solutions has seen its short term share price return fall 22.8% over the past 30 days and 41.6% over 90 days, while the year to date...

Trade policy is back in the spotlight as new US tariffs, legal challenges from 25 states, and pushback from Mexico’s President Claudia Sheinbaum put cross border commerce under fresh pressure. That kind of uncertainty can punish some companies while opening doors for others that rely more on US based manufacturing. This article walks through three US Domestic Manufacturing stocks exposed to this news and explains how these shifts could matter for your portfolio. The three US domestic...

UroGen Pharma stock rose 16.3% to US$46.43 on the first trading day after earnings, a sharp move for a company still carrying material losses. The market is reacting to one key factor: revenue is increasing much faster than the income statement pain. Q2 revenue reached US$72.5m, powered by ZUSDURI and supported by steady JELMYTO sales, while the company still reported a net loss of US$14.4m. For a biotech long viewed through the lens of cash burn and balance sheet strain, this quarter...

In the second quarter of 2026, Mohawk Industries reported higher sales of US$2,991.4 million and net income of US$196.1 million, with earnings per share rising meaningfully year over year, and completed a US$206.4 million share repurchase program covering 1,915,000 shares since July 2025. The results highlight broad-based margin improvement supported by pricing actions, productivity gains, and restructuring initiatives, achieved despite ongoing weakness in residential flooring demand and...

SpaceX has just shocked the market by pouring $18.4b into AI projects, with spending far beyond its recent revenue jump and sending the stock sharply lower. That kind of aggressive move can reshuffle where capital flows across the wider AI infrastructure space. This article walks through 3 stocks exposed to this news, explaining how they might be affected by the surge in cloud and compute demand and outlining where key risks could sit. The stocks covered below are just a starting sample from...

CorVel’s stock jumped 5.9% to US$62.57 into the close, which indicates traders responded positively to the results. The key point is that the earnings beat was meaningful. Revenue reached about US$259.9m and basic earnings per share came in near US$0.63, with the quarter supported by strong performance in payment integrity and broader workers’ compensation services. CorVel entered this report with mixed short-term returns but a solid earnings track record and a valuation that already sat...

Boyd Gaming (BYD) has drawn investor attention after releasing its second quarter and half year 2026 results, which showed steady revenue along with lower net income and slightly softer earnings per share. See our latest analysis for Boyd Gaming. Boyd Gaming's latest earnings update has coincided with softer trading, with the share price at US$84.32 and a 7 day share price return that fell 7.13%. In contrast, the 1 year total shareholder return of 2.14% and 5 year total shareholder return of...

Hudson Pacific Properties stock jumped 7.1% to US$14.97 after the Q2 release, a sharp move for a company that came into today with a flat week and a tough recent track record. The headline was not earnings per share. The market latched on to a different story. Core funds from operations, or core FFO, nearly tripled to US$23.1 million and management nudged full year core FFO guidance higher. The short term price pop is about relief and renewed confidence. The bigger question for you is whether...

AST SpaceMobile stock has delivered extremely strong multi year returns, yet the current valuation checks and recent share price swings suggest the market may now be paying up for that story rather than offering clear value. AST SpaceMobile has returned roughly 14x over the past 3 years. This puts extra pressure on today’s investors to judge whether expectations have run ahead of fundamentals. Progress on its space based cellular network, including recent BlueBird satellite launches and...

Ultragenyx Pharmaceutical stock slipped 3.4% to about US$24.93 as investors digested a fresh set of numbers that mixed record sales with continued losses. Q2 revenue reached US$214m, led by rare disease drugs such as Crysvita, while the company still reported a net loss of US$92m, or US$0.90 per share. For traders focused on this week, that loss keeps the pressure on. For investors thinking in years rather than days, the key points are the record top line, the active late stage pipeline and...

In the second quarter of 2026, Jones Lang LaSalle reported higher sales of US$6,927.9 million and net income of US$215.6 million year over year, affirmed its mid- to high single-digit revenue growth target for 2026, and completed a multiyear buyback totaling 8,106,124 shares for US$1.82 billion. Together, the stronger earnings, reaffirmed growth outlook, and sizeable share repurchases highlight management’s confidence in the business and the company’s focus on enhancing per-share...

Guardant Health stock has delivered very strong returns over the past few years, yet the signals on what that means for valuation are mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market multiples suggest the shares screen expensive. Guardant Health has returned 347.6% over the past three years, which puts extra focus on whether the current share price leaves much margin for error. Growing adoption of the Guardant360 and Shield blood tests may...

Deckers Outdoor recently reported first-quarter 2026 results, showing sales of US$1,019.53 million and net income of US$129.97 million, while also updating full-year 2027 guidance to higher expected revenue, slightly better than 21.5% operating margin, and diluted EPS of US$7.35–US$7.50 supported by ongoing share repurchases. The company’s decision to tie its raised earnings outlook to repurchasing shares worth roughly 80% of projected fiscal 2027 free cash flow underlines how capital...

FRP Holdings stock slipped 2.4% to US$21.93 after its Q2 report, yet the real story sits in a different place than the share chart. The headline this quarter is a squeeze on profitability. Trailing net profit margin has compressed to 0.3% compared with 16.5% a year earlier, and reported earnings over the past five years have retreated at an average rate of 45.8% a year. Investors are reacting to that margin picture more than to the solid real estate platform or cash on hand. The question now...

Marqeta stock just handed investors a 7% one day drop, yet the earnings story leans far more toward a profitability grind than a collapse. Coming into the print, the stock had been roughly flat over three months, with only a small gain over 30 days. Then the market met a payments platform that printed about US$176m in Q2 net revenue and roughly US$8m in net income, its second straight profitable quarter. The real headline is margin power. Adjusted earnings before interest, tax, depreciation...

Penske Automotive Group recently reported past second-quarter 2026 results, with sales rising to US$8,297.2 million while net income eased to US$260.4 million and basic earnings per share from continuing operations slipped to US$3.96. Over the same period, the company also continued its long-running repurchase program, buying 94,711 shares for US$16.1 million and bringing total buybacks under the 2010 authorization to 31.05 million shares, or 38.85% of its shares at launch. We’ll now examine...

Blackstone (BX) is in focus after reporting second quarter results on July 23, 2026, that showed higher revenue and net income compared with a year earlier, alongside a larger quarterly dividend for shareholders. See our latest analysis for Blackstone. At a share price of $136.03, Blackstone has seen a 7 day share price return of 5.12% and a 30 day share price return of 10.22%. Year to date the share price return is down 14.34%, while the 3 year total shareholder return of 49.50% points to a...

Louisiana-Pacific stock barely budged after earnings, up just 0.7% to US$77.36, yet the quarter itself was anything but quiet. The company posted Q2 2026 revenue of US$664m and basic earnings per share of US$0.37, with investors weighing those construction cycle exposed numbers against a rich trailing P/E of about 100x. The real story for you is the squeeze between modest profits and a high multiple, especially with trailing net profit margin running at 2.2% and a recent one off loss still...

Zeta Global Holdings went into this earnings print as a high growth marketing and AI platform stock with a loyal bull camp and a lot to prove on profitability. The market liked what it saw. The share price jumped 11.6% to US$27.07 after the release, extending a strong three month run. The headline this quarter is profit. Zeta Global Holdings shifted from a loss in Q1 to GAAP net income of US$8.2 million, with basic earnings per share of US$0.03, on revenue of US$442.8 million. That move into...

Moderna (NasdaqGS:MRNA) has started the first Phase 1 clinical trial of an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus. The trial follows authorization from Health Canada and is conducted in partnership with the Coalition for Epidemic Preparedness Innovations, or CEPI. Moderna and CEPI have pledged to support access to the Bundibugyo ebolavirus vaccine for low and middle income countries if it is approved. For investors watching how Moderna's mRNA platform extends beyond...

Healthpeak Properties stock barely budged, up less than 1% to around US$21.79, even though the earnings story was all about stronger cash generation. For a real estate investment trust, funds from operations is what matters, and Healthpeak reported adjusted funds from operations of US$0.46 per share in the quarter with total revenue of US$771.6m. The market reaction looks muted compared with that core cash figure and a raised full year adjusted funds from operations guidance range. Investors...

Banc of California, Inc. reported second-quarter 2026 results showing net interest income of US$250.5 million but a net loss of US$241.35 million, a reversal from net income a year earlier, alongside basic and diluted losses per share of US$1.61 from continuing operations. The quarter also saw net charge-offs surge to US$160,281,000 from US$44,222,000 a year ago, highlighting a sharp deterioration in credit costs even as management emphasized balance sheet repositioning efforts. We’ll now...

What the latest Lamb Weston guidance tells you Lamb Weston Holdings (LW) has just paired mixed fourth quarter and full year earnings with cautious fiscal 2027 guidance, flagging expected net sales growth of 0.0% to 1.0% alongside softer profitability measures. For you as an investor, that combination of modest sales expectations, declining net income and earnings per share, and commentary on waning demand presents questions about how the stock reflects slower organic growth and international...